Strategies for Anticoagulation During Venovenous ECMO

Study Overview
=================
Brief Summary
-----------------
Moderate intensity titrated dose anticoagulation has been used in patients receiving extracorporeal membrane oxygenation (ECMO) to prevent thromboembolism and thrombotic mechanical complications. As technology has improved, however, the incidence of thromboembolic events has decreased, leading to re-evaluation of the risks of anticoagulation, particularly during venovenous (V-V) ECMO. Recent data suggest that bleeding complications during V-V ECMO may be more strongly associated with mortality than thromboembolic complications, and case series have suggested that V-V ECMO can be safely performed without moderate or high intensity anticoagulation. At present, there is significant variability between institutions in the approach to anticoagulation during V-V ECMO. A definitive randomized controlled trial is needed to compare the effects of a low intensity fixed dose anticoagulation (low intensity) versus moderate intensity titrated dose anticoagulation (moderate intensity) on clinical outcomes during V-V ECMO. Before such a trial can be conducted, however, additional data are needed to inform the feasibility of the future trial.

Detailed Description
-----------------
Since the inception of Extracorporeal Membrane Oxygenation (ECMO), moderate intensity titrated dose anticoagulation has been used to prevent clinically harmful thromboembolism and thrombotic mechanical complications. The impact of thromboembolic events on clinical outcomes during venovenous (V-V) extracorporeal membrane oxygenation (ECMO), however, is unclear, and complications related to bleeding are common and associated with increased morbidity and mortality. These findings have led many experts to suggest that anticoagulation strategies during V-V ECMO should be re-evaluated. Critical illness, in general, is associated with both coagulopathy and impaired hemostasis. These problems are compounded during ECMO by the artificial interface between blood and the non-biologic surface of the circuit components, which leads to activation of the coagulation system, consumptive thrombocytopenia, fibrinolysis, and thrombin generation. The sheer stress on blood components during ECMO also lead to destruction of high-molecular-weight von Willebrand multimers, interrupting primary hemostasis. Both bleeding and thromboembolism are common complications during ECMO. Bleeding events have been associated with poor clinical outcomes, likely mediated by an increased incidence of intracranial hemorrhage during ECMO. During intra-operative cardiopulmonary bypass and venoarterial (V-A) ECMO, ischemic strokes are a common and potentially deadly complication. During V-V ECMO, however, the majority of thromboembolic events are cannula-associated DVT and circuit thromboses requiring exchange, which are of unclear clinical significance. Various anticoagulation strategies have been proposed to balance the risks of bleeding and thromboembolism during V-V ECMO, including high intensity anticoagulation, moderate intensity anticoagulation, and low intensity anticoagulation (the equivalent of DVT prophylaxis). Observational studies have suggested that, compared to moderate intensity anticoagulation, low intensity anticoagulation reduces transfusion requirements without affecting the incidence of thrombosis, hemorrhage, or death. In one case series of 60 patients who were treated with only low-intensity subcutaneous heparin during V-V ECMO, rates of transfusions were lower than historical controls without any effect on the rate of thrombotic events. Similarly, a recent systematic review suggested that the rates of thromboembolism and circuit thrombosis among patients managed with a moderate intensity anticoagulation strategy during V-V ECMO were comparable to the rates reported among patients managed with a less intense anticoagulation strategy. To date, there are no randomized controlled trials comparing low intensity to moderate intensity anticoagulation during V-V ECMO. Guidelines from the Extracorporeal Life Support Organization (ELSO), the pre-eminent group for ECMO education and research, provide little guidance for the selection of anticoagulation strategy, and anticoagulation practices are highly variable across institutions. A large, multicenter, randomized trial is needed to determine the ideal strategy to anticoagulation during V-V ECMO. Before such a trial can be conducted, however, additional data are needed on the feasibility of randomizing patients to a specific anticoagulation strategy and study measurements. To facilitate a large, multicenter randomized controlled trial comparing low intensity anticoagulation to moderate intensity anticoagulation during V-V ECMO, a pilot trial is needed to establish feasibility and the performance of the primary outcome measures. Primary aim of the study: To demonstrate feasibility of a future large, multi-center randomized controlled trial comparing low intensity to moderate intensity anticoagulation among adults receiving V-V ECMO by demonstrating the ability to recruit and randomize participants, adhere to assigned anticoagulation strategy, and demonstrate adequate separation between groups in therapy delivered and intensity of anticoagulation achieved with the assigned anticoagulation strategies. Secondary aim of the study: To define and estimate the frequency of the primary efficacy, primary safety, and secondary outcomes of a future large, multi-center randomized controlled trial comparing low intensity vs moderate intensity anticoagulation among adults receiving V-V ECMO.

Official Title
-----------------
Strategies for Anticoagulation During Venovenous ECMO: The SAFE-ECMO Pilot Trial

Conditions
-----------------
Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism

Intervention / Treatment
-----------------
* Other: Low intensity anticoagulation
* Other: Moderate Intensity Anticoagulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient receiving V-V ECMO Patient is located in a participating unit of the Vanderbilt University Medical Center (VUMC) adult hospital. Exclusion Criteria: Patient is pregnant Patient is a prisoner Patient is < 18 years old Patient underwent ECMO cannulation greater than 24 hours prior to screening Presence of an indication for systemic anticoagulation: Ongoing receipt of systemic anticoagulation Planned administration of anticoagulation for an indication other than ECMO Presence of or plan to insert an arterial ECMO cannula Presence of a contraindication to anticoagulation: Active bleeding determined by treating clinicians to make anticoagulation unsafe Major surgery or trauma less than 72 hours prior to randomization Known history of a bleeding diathesis Ongoing severe thrombocytopenia (platelet count < 30,000) History of heparin-induced thrombocytopenia (HIT) Heparin allergy Positive SARS-CoV-2 test within prior 21 days or high clinical suspicion for COVID-19 The treating clinician determines that the patient's risks of thromboembolism or bleeding necessitate a specific approach to anticoagulation management during V-V ECMO

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Single center, open-label, parallel-group, randomized pilot trial
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low Intensity Anticoagulation<br>For patients assigned to the low intensity anticoagulation strategy, clinical teams will be instructed to initiate low intensity anticoagulation at doses and frequencies commonly used for deep vein thrombosis (DVT) prophylaxis. The choice of anticoagulant, dose, and frequency of administration will be deferred to treating clinicians. | Other: Low intensity anticoagulation<br>* Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.<br>|
| Active Comparator: Moderate Intensity Anticoagulation<br>For patients assigned to the moderate intensity anticoagulation group, clinical teams will be instructed to initiate a continuous infusion of moderate intensity anticoagulation targeting either a partial thromboplastin time (PTT) of 40-60 seconds or an Anti-Xa level of 0.2 to 0.3 IU/mL. The choice of anticoagulant and approach to dosing will be deferred to treating clinicians. | Other: Moderate Intensity Anticoagulation<br>* Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation. This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of major bleeding events | Major bleeding event, according to the International Society on Thrombosis and Hemostasis, defined as: Fatal bleeding Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome Clinically overt bleeding associated with either a drop in hemoglobin level by at least 2.0 grams/dL or leading to transfusion of two or more units of packed red blood cells | From randomization to until the date of death or the date 24 hours after decannulation, whichever came first, through study completion, an average of 2 years. | 
| Frequency of thromboembolic events | Thromboembolic event defined as: Deep venous thrombosis (DVT) Acute pulmonary embolism (PE) Intra-cardiac thrombosis Ischemic stroke Acute circuit thrombosis requiring urgent circuit exchange Acute arterial thromboembolism | From randomization to until the date of death or the date 24 hours after decannulation, whichever came first, through study completion, an average of 2 years. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of cannula-associated deep vein thrombosis | Cannula-associated deep vein thrombosis, as measured by four-extremity venous ultrasounds obtained 24-72 hours following decannulation among patients who were decannulation | 24-48 hours after decannulation | 
| Bleeding events per ECMO day | Number of major bleeding events per day of V-V ECMO | From from randomization to 24 hours after decannulation | 
| Thromboembolic events per ECMO day | Number of thromboembolic events per day of V-V ECMO | From from randomization to 24 hours after decannulation | 
| Bleeding events from randomization to the first of death or discharge | Number of bleeding events from date of randomization until the date of death or hospital discharge, whichever came first, up to 100 months | From date of randomization until the date of death or hospital discharge, whichever came first, through study completion, an average of 2 years. | 
| Thromboembolic events from randomization to the first of death or discharge | Number of thromboembolic events from randomization until the date of death or hospital discharge, whichever came first, up to 100 months | From randomization until the date of death or hospital discharge, whichever came first, through study completion, an average of 2 years. | 
| Frequency of circuit or circuit component exchanges | Circuit or circuit component exchange during ECMO support | From randomization to the date of death or decannulation, whichever came first, through study completion, an average of 2 years. | 
| ECMO circuit durability | The number of calendar days from randomization to death or decannulation divided by the Number of ECMO circuits used | From randomization to the date of death or decannulation, whichever came first, through study completion, an average of 2 years. | 
| Red blood cell transfusion volume per ECMO day | Total volume of packed red blood cells transfused from randomization to death or decannulation divided by the number of calendar days during this period | From randomization to the date of death or decannulation, whichever came first, through study completion, an average of 2 years. | 
| New Heparin Induced Thrombocytopenia diagnosis | New diagnosis of Heparin Induced Thrombocytopenia as measured by clinically obtained serotonin release assay | From randomization to the date of death or decannulation, whichever came first, through study completion, an average of 2 years. | 
| Lowest platelet count | Lowest clinically obtained platelet count | From randomization to the the date of death or the date 24 hours after decannulation, whichever came first, through study completion, an average of 2 years. | 
| Highest total and indirect bilirubin values | Highest clinically obtained total and indirect bilirubin values | From randomization to the the date of death or the date 24 hours after decannulation, whichever came first, through study completion, an average of 2 years. | 
| Highest lactate dehydrogenase value | Highest clinically obtained lactate dehydrogenase value | From randomization to the the date of death or the date 24 hours after decannulation, whichever came first, through study completion, an average of 2 years. | 
| Death attributable to a major bleeding event | In-hospital mortality attributable to a major bleeding event | From randomization to the date of death or discharge, whichever came first, through study completion, an average of 2 years. | 
| Death attributable to a thromboembolic event | In-hospital mortality attributable to a thromboembolic event | From randomization to the date of death or discharge, whichever came first, through study completion, an average of 2 years. | 
| Ventilator-free days | Number of days alive and free from mechanical ventilation between randomization and day 28. | From randomization to the date of death or discharge, whichever came first, through study completion, an average of 2 years. | 
| ICU-free days | Number of days alive and not in the ICU between randomization and day 28. | From randomization to the date of death or discharge, whichever came first, through study completion, an average of 2 years. | 
| Hospital-free days | Number of days alive and not in the hospital between randomization and day 28. | From randomization to the date of death or discharge, whichever came first, through study completion, an average of 2 years. | 
| In-hospital mortality | Death prior to hospital discharge | From randomization to the date of death or discharge, whichever came first, through study completion, an average of 2 years. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ARDS, Hypoxemic respiratory failure, Extracorporeal Membrane Oxygenation